- Key highlights include near universal engraftment and no 100-day non-relapse mortality in patients randomized to Iomab-B arm; 79% of patients in the control arm failed to achieve a complete response necessary for conventional bone marrow transplant
- 67% (10/15) of patients eligible for crossover successfully transplanted with Iomab-B
- Interim results strongly support feasibility of Iomab-B for targeted conditioning in patients 55 years or older with active, relapsed or refractory Acute Myeloid Leukemia
- SIERRA trial is the only ongoing Phase 3 trial to offer a bone marrow transplant for this patient population
PR Newswire
NEW YORK, Dec. 4, 2018
